Invention herewith described refers to the once-a-day oxycodone formulations and is directed to the formulations with the delayed-release which contain oxycodone or its pharmaceutically acceptable salt that provide the average C24/Cmax oxycodone ratio from 0.6 to 1.0 after administering orally to patients in stable condition and the procedures derived from it.Pronalazak je usmeren na formulacije sa odloženim oslobađanjem koje sadrže oksikodon ili njegovu farmaceutski prihvatljivu so koji obezbeđuju srednji C24/Cmax odnos oksikodona od 0,6 do 1,0 posle davanja oralnim putem pri stabilnom stanju pacijentima i na postupke izvedene odatle.
